Haloperidol discontinuation for schizophrenia
Referencias
Additional references
Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
Berger M. Mental illness. Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. Urban & Fischer, 2003.
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11.
Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681‐90.
Deeks J. Issues in the selection for meta‐analyses of binary data. The 8th International Cochrane Colloquium. Cape Town: The Cochrane Collaboration, 25‐28 Oct 2000.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34.
Essali MA, Maddocks PD. Seventeen years in the life of a depot neuroleptic clinic ‐ an audit study of schizophrenia and other psychosis. British Journal of Medical Economics 1993;6:3‐11.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30.
Irving CB, Adams CE, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003082.pub2]
Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: An update. Clinical Pharmacokinetics 1999;37:435‐56.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71.
Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183‐91.
Lohse MJ, Müller‐Oerlinghausen B. Psychopharmaka. In: Schwabe U, Pfaffrath D editor(s). Arzneimittelverordnungsreport. Heidelberg: Springer, 2009:767‐810.
López‐Munoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Research Bulletin 2009;79:130‐41.
Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52.
Marvaha S, Johnson S. Schizophrenia and employment ? A review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337‐49.
McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiology 2008;30:67‐76.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five‐year follow‐up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine. Monograph supplement 1989;15:1‐46.
Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153‐5.
Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.
Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'H C, Maziere B, et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 2001;179:503‐8.
